Bonnie Hill, APRN
Family · Louisa, KYNPI 1538585385
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $268,000 of the $371,834 with a category attached, or 72.1%. AbbVie accounts for 75.6% of it on its own, with 21 other manufacturers making up the rest. Among family clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,230 payments — averaging $302.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$281K
- Madrigal Pharmaceuticals$27K
- Gilead$23K
- Evoke Pharma, Inc.$17K
- Aimmune Therapeutics, Inc.$14K
- Nestle Healthcare Nutrition Inc.$5K
- plus $4K from 16 others
What the payments were for
- Consulting fees$20,6186%
- Speaking & faculty fees$268,00072%
- Travel & lodging$64,23017%
- Food & beverage$18,8705%
- Education$1160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 672 | $281,272 |
| Madrigal Pharmaceuticals | 59 | $26,740 |
| Gilead | 76 | $23,348 |
| Evoke Pharma, Inc. | 33 | $17,064 |
| Aimmune Therapeutics, Inc. | 47 | $13,919 |
| Nestle Healthcare Nutrition Inc. | 27 | $5,365 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 194 | $2,151 |
| Johnson & Johnson | 28 | $611 |
| Redhill Biopharma Inc. | 31 | $321 |
| Novo Nordisk | 9 | $187 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $177 |
| Phathom Pharmaceuticals, Inc. | 13 | $176 |
| Regeneron Healthcare Solutions, Inc. | 5 | $82 |
| Bristol Myers Squibb | 5 | $82 |
| Sanofi | 4 | $79 |
| Ardelyx, Inc. | 4 | $71 |
| Lilly USA, LLC | 4 | $61 |
| Merck | 2 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| QOL Medical, LLC | 2 | $29 |
| Celltrion USA Inc. | 1 | $17 |
| Enterra Medical, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$371,834 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 25 | $281,001 |
| XifaxanRifaximin | 64 | $202,694 |
| RezdiffraResmetirom | 31 | $134,443 |
| LinzessLinaclotide | 150 | $121,092 |
| Dupixent PenDupilumab | 13 | $97,297 |
| Entyvio PenVedolizumab | 15 | $95,018 |
| MounjaroTirzepatide | 82 | $90,682 |
| RelistorMethylnaltrexone Bromide | 26 | $79,146 |
| GimotiMetoclopramide Hcl | 30 | $68,717 |
| CreonLipase/Protease/Amylase | 26 | $54,431 |
| OzempicSemaglutide | 48 | $46,097 |
| ViberziEluxadoline | 25 | $44,045 |
| TrulancePlecanatide | 39 | $38,766 |
| IbsrelaTenapanor Hcl | 12 | $36,318 |
| VemlidyTenofovir Alafenamide | 21 | $30,145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Relistor, Trulance | $2,151 | $320,606129 claims |
| AbbVieLinzess, Creon, Viberzi | $281,272 | $219,567201 claims |
| Madrigal PharmaceuticalsRezdiffra | $26,740 | $134,44331 claims |
| Lilly USA, LLCMounjaro | $61 | $90,68282 claims |
| Evoke Pharma, Inc.Gimoti | $17,064 | $68,71730 claims |
| Novo NordiskOzempic | $187 | $46,09748 claims |
| Ardelyx, Inc.Ibsrela | $71 | $36,31812 claims |
| GileadVemlidy | $23,348 | $30,14521 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity, Dexilant | $177 | $29,50839 claims |
| Redhill Biopharma Inc.Movantik | $321 | $17,65423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.
Other family in Louisa
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
- Carrie Parrish NyekanBowling Green$55K
- Alisha ClemonsLexington$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.